 The biopharmaceutical industry's antibody therapy pipeline remains strong, with six new antibody therapeutics gaining approval in 2019 and another nine expected to be approved by the end of 2019. Additionally, 79 novel antibodies are currently being evaluated in late-stage clinical trials, including 40 for cancer treatment. This article was authored by Helen Kaplan, Minalini Maliduan, Tita Schneider, and others.